what they said (Hover the mouse cursor over underlined words for more info)
A new vaccine against shingles has received U.S. regulatory approval but it's not clear when the product, Zostavax, will be available to Canadians, too.
The U.S. Food and Drug Administration last week gave Merck & Co. Inc. the go-ahead for Zostavax.
Shingles, also called herpes zoster, strikes when the chickenpox virus reactivates and resumes reproducing after lying dormant, sometimes for decades, in nerve cells in the body. The vaccine is only for adults who previously have had chickenpox.
A spokesperson for Merck's Canadian subsidiary, Merck Frosst Canada Ltd., said it hopes to bring Zostavax to the Canadian market as well....
The original article can found in the Media Doctor archives.
what we said (Hover the mouse cursor over underlined words for more info)
This article is a reasonably accurate story about a new vaccine designed to prevent the development of shingles in people who have previously had chickenpox. The one area of the article that could have been better developed is a discussion of the severity of symptoms that shingles causes. While it can cause considerable disability in some people others have relatively mild symptoms.